Association of the recurrence of vocal leukoplakia with MDM2-309 variants over a 2-year period: a prospective study. (2nd January 2016)

• Record Type: Journal Article
• Authors: Zhou, Jian; Yang, Yue; Zhang, Duo; Zhou, Liang; Liu, Fei; Tao, Lei; Lu, Li-Ming
• Is Part Of: Acta oto-laryngologica. Volume 136:Number 1(2016)
• Page Start: 95
• Page End: 99
• Publication Date: 2016-01-02
• Subjects: Cancerization -- genotype variants -- laryngeal carcinoma -- MDM2 -- recurrence -- vocal leukoplakia; Otolaryngology -- Periodicals; Ear -- Diseases -- Periodicals; Throat -- Diseases -- Periodicals; Otolaryngology -- Electronic Resources; Otorhinolaryngologic Diseases; 617.8
• DOI: 10.3109/00016489.2015.1082194
• Languages: English
• ISSNs: 0001-6489

Abstract

Abstract: Conclusion : MDM2-309 polymorphism variant genotypes decrease the risk of recurrence in vocal leukoplakia. Objective : The results of a previous study 2 years ago showed the effect of mouse double minute 2 homolog (MDM2) SNP309 polymorphisms in people with laryngeal carcinoma and vocal leukoplakia (a pre-cancerous laryngeal carcinoma lesion). This prospective, clinical trial was performed to assess the relationship between MDM2-309 polymorphism variants and recurrence/cancerization rates in people with vocal leukoplakia over a 2-year period. Participants and method : A total of 61 post-operative patients with vocal leukoplakia participated in this prospective, observational, 2-year, follow-up study, and were genotyped for the MDM2-309 gene using pyrosequencing. Recurrence and cancerization rates were used to assess the relationship between the clinical outcome and the genotype variants. Results : The recurrence rate in the GT genotypes group was lower than that in the normal TT genotype group (17.2% vs 50%, p = 0.05) and there was a significantly lower recurrence rate in the GG genotype group than in the normal TT genotype group (10% vs 50%, p = 0.03). However, there was no statistically significant difference in the cancerization rate between the MDM2-309 variant (GT + GG) genotypes group and the normal TT genotype group (12.2% vs 8.3%, p > 0.05) over the 2-year follow-up period.